View Article

Abstract

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer linked with a grim prognosis and restricted treatment options. The necessity for confirmed prognostic and predictive biomarkers remains crucial to steer treatment choices and prognostic assessments. This article delves into both established and evolving prognostic and predictive biomarkers of TNBC, coupled with emerging and authorized therapeutic approaches. The spectrum of biomarkers assessed encompasses epidermal growth factor receptor (EGFR), vascular endothelial growth factors (VEGF), fibroblast growth factor receptor (FGFR), human epidermal growth factor receptor 2 (HER2), androgen receptor, oxidative stress/redox signaling, microRNAs, TP53 mutation, breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutation/homologous recombination deficiency (HRD), NTRK gene fusion, PI3K/AKT/mTOR pathway, immune-related biomarkers (such as programmed death-ligand 1 (PDL1), tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), neoantigens, flaws in DNA mismatch repair proteins (dMMR)/microsatellite instability-high (MSI-H)). Additionally, the study scrutinizes novel targets of antibody?drug conjugates and residual disease. The integration of biomarker-guided strategies in TNBC management is witnessing growth, consequently broadening the horizons of available options for individuals afflicted by this specific breast cancer subtype. Research endeavors persist in their pursuit of identifying supplementary biomarkers and pinpointing targeted treatment avenues, all in the overarching aim of enhancing clinical outcomes and extending survival rates.

Keywords

triple-negative breast cancer; biomarkers; prognostic

Reference

  1. Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. PMID: 33198517; PMCID: PMC8174647.
  2. Sultana R, Kataki AC, Barthakur BB, Sarma A, Bose S. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study. Curr Probl Cancer. 2020 Oct;44(5):100556. doi: 10.1016/j.currproblcancer.2020.100556. Epub 2020 Feb 3. PMID: 32044043.
  3. Mehta M, Griffith J, Panneerselvam J, Babu A, Mani J, Herman T, Ramesh R, Munshi A. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. Int J Radiat Biol. 2021;97(8):1109-1120. doi: 10.1080/09553002.2020.1730012. Epub 2020 Mar 2. PMID: 32052681; PMCID: PMC7882427.
  4. Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treat Rev. 2018 Jan;62:1-8. doi: 10.1016/j.ctrv.2017.10.008. Epub 2017 Oct 31. PMID: 29126017.
  5. da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020 Jan;145:102855. doi: 10.1016/j.critrevonc.2019.102855. Epub 2019 Dec 20. PMID: 31927455.
  6. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098. PMID: 15681523
  7. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26. PMID: 32335505.
  8. Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24. PMID: 30040523; PMCID: PMC6118403.
  9. Perez-Garcia J, Muñoz-Couselo E, Soberino J, Racca F, Cortes J. Targeting FGFR pathway in breast cancer. Breast. 2018 Feb;37:126-133. doi: 10.1016/j.breast.2017.10.014. Epub 2017 Nov 20. PMID: 29156384.
  10. Jafarian AH, Kooshkiforooshani M, Farzad F, Mohamadian Roshan N. The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors. Iran J Pathol. 2019 Fall;14(4):299-304. doi: 10.30699/ijp.2019.96713.1952. Epub 2019 Sep 22. PMID: 31754359; PMCID: PMC6824770.
  11. Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takeshita T, Inao T, Iwase H. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci. 2016 Apr;107(4):491-8. doi: 10.1111/cas.12897. Epub 2016 Mar 28. PMID: 26801869; PMCID: PMC4832856.
  12. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, Liang X, Sun Q, Pang D. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2012 Jun 15;105(8):773-9. doi: 10.1002/jso.22120. Epub 2011 Oct 17. PMID: 22006548.
  13. Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21. Erratum in: J Clin Oncol. 2017 Mar 10;35(8):926. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):358. PMID: 27870574; PMCID: PMC6865065.
  14. Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8. PMID: 26646757.
  15. Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021 Jul;72:136-145. doi: 10.1016/j.semcancer.2020.06.005. Epub 2020 Jun 13. PMID: 32544511.
  16. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069
  17. Eggemann H, Ignatov T, Burger E, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer. 2015;22(5):725–733. PMID: 26187126.
  18. Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 Feb 10;38(5):444-453. doi: 10.1200/JCO.19.01455. Epub 2019 Dec 10. PMID: 31821109; PMCID: PMC7007289.
  19. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Erratum in: Lancet Oncol. 2019 May 10;: PMID: 31047803.
  20. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12. PMID: 29420467; PMCID: PMC5808581.
  21. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 1;3(9):1266-1273. doi: 10.1001/jamaoncol.2016.4975. PMID: 28301631.
  22. Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014 Jul 16;4(4):353-68. PMID: 25057438; PMCID: PMC4106653.
  23. Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, Ramírez-Tortosa CL, Álvarez M, Llácer C, Zarcos-Pedrinaci I, Carrasco E, Caballero R, Martín M, Alba E. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018 May 29;9(41):26406-26416. doi: 10.18632/oncotarget.25413. PMID: 29899867; PMCID: PMC5995183.
  24. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21. PMID: 23965901; PMCID: PMC4086643.
  25. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. PMID: 29373071; PMCID: PMC5858523.
  26. M.V.Giuli , E. Giuliani et al. Notch signaling activation as ahallmarkfot triple- negative breast cancer. Journal of Oncology . 2019 July 11. Doi: 10.1155/2019/8707053.
  27. Shenting Liu , He Xu et al. Oxidative stress genes define two subtypes of triple- negative breast cancer with prognostic and therapeutic implications .Frontiers in Genetics . 2023, 14:1230911.DOI:10.3389/fgene.2023.1230911.
  28. PragatheiswarGiri , Ignacio G .Camarillo. Enhancement of reactive oxygen species production in triple negative breast cancer cells treated with electric pulses and resveratrol. Explore Target Antitumor Ther.2023;4:42-56, DOI : https;//doi.org/10.37349/etat.2023.00122
  29. Elvira D ‘ Ippolito et al. MicroRNAs and Triple Negative Breast Cancer. International Journal of Molecular Sciences.Published : 11 November 2013.
  30. Zhu, S.; Wu, H. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18, 350–359
  31. Sugita BM, Pereira SR, de Almeida RC, et al. Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients. Oncotarget. 2019;10(58):6184–6203. [PubMed: 31692930]
  32. Yang F, Zhang W, Shen Y, et al. Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol. 2015;46(3):927–932. [PubMed: 25571912]
  33. Zahi l.Mitri ,Nour Abuhadra et al. Impact of TP53 mutations in triple negative breast cancer. Precision Oncology .Article no: 64,Published on :09 September  2022 .
  34. Iuliana Shapira ,Annette Lee et al . P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Critical reviews in Oncology / Hematology.Volume: 88,Issue -2 , November 2013 , Pages 284-292.
  35. Boya Lu, MD, Elango Natarajan olecular Classification, Treatment, and Genetic Biomarkers  in Triple-Negative Breast Cancer: A Review.Technology in cancer research and  treatment. Volume 22 1-10.
  36. Rania Chehade,Arizona A Awan et al. A narrative review of biomarkers in advanced triple negative breast cancer. Precision Cancer Medicine. Volume 4 ,September  30,2021.
  37. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16 (2):110–120. [PubMed: 26775620
  38. 38.Lin PH, Chen M, Tsai LW, et al. Using next-generation sequencing to redefine BRCAness in triplenegative breast cancer. Cancer Sci. 2020;111(4):1375–1384. [PubMed: 31958182] .
  39. Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19 (4):497–509. [PubMed: 29501363]
  40. Wolf DM, Yau C, Sanil A, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31. [PubMed: 28948212]
  41. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2--mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637. [PubMed: 29713086] .
  42. Telli ML, Hellyer J, Audeh W, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018;168(3):625–630. [PubMed: 29275435] • This study illustrates high HRD score is associated with improved response to neoadjuvant chemotherapy, independent of gBRCA mutation.
  43. Federica Zito Marino, Simona Buono et al. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC,FISH,RT-PCR and NGS. The Journal of Pathology . May 2023. 9(5), DOI : 10.1002/cjp2.324.
  44. Arielle J.Medford, Lauren Oshry et al. TRK inhibitor in a patient with metastatic  triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic Advances in Medical Oncology.Published online January 30,2023, https://doi.org/10.1177/17588359231152844.
  45. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282. [PubMed: 31838007]
  46. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017 Apr;45:62-71. doi: 10.1016/j.ceb.2017.02.007. Epub 2017 Mar 24. PMID: 28343126; PMCID: PMC5482768.
  47. Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020 Dec 26;22(1):173. doi: 10.3390/ijms22010173. PMID: 33375317; PMCID: PMC7796017.
  48. Solinas G, Becattini B. PI3K and AKT at the Interface of Signaling and Metabolism. Curr Top Microbiol Immunol. 2022;436:311-336. doi: 10.1007/978-3-031-06566-8_13. PMID: 36243850.
  49. Faes S, Dormond O. PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci. 2015 Sep 3;16(9):21138-52. doi: 10.3390/ijms160921138. PMID: 26404259; PMCID: PMC4613246.
  50. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10. PMID: 24764583; PMCID: PMC4000553.
  51. Kumar A, Watkins R, Vilgelm AE. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Front Immunol. 2021 Jun 1;12:690499. doi: 10.3389/fimmu.2021.690499. PMID: 34140957; PMCID: PMC8204054.
  52. Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2022 Jun;31(6):549-555. doi: 10.1080/13543784.2022.2008354. Epub 2021 Nov 25. PMID: 34793275.
  53. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016 Oct 18;4:59. doi: 10.1186/s40425-016-0165-6. PMID: 27777769; PMCID: PMC5067916.
  54. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021 Feb 8;39(2):154-173. doi: 10.1016/j.ccell.2020.10.001. Epub 2020 Oct 29. PMID: 33125859; PMCID: PMC7878292
  55. Ritterhouse LL. Tumor mutational burden. Cancer Cytopathol. 2019 Dec;127(12):735-736. doi: 10.1002/cncy.22174. Epub 2019 Aug 21. PMID: 31433548.
  56. Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, Ding R, Yang R, Tan J, Zhang L, Zhang Y, Wang Y, Dong C, Li Y. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022 Mar 17;13:795972. doi: 10.3389/fimmu.2022.795972. PMID: 35371084; PMCID: PMC8968082.
  57. Song Y, Gu Y, Hu X, Wang M, He Q, Li Y. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment. Onco Targets Ther. 2021 Aug 16;14:4485-4497. doi: 10.2147/OTT.S324641. PMID: 34429613; PMCID: PMC8379685.
  58. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6. PMID: 31443694; PMCID: PMC6708248.
  59. Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol. 2021 Apr 16;12:672356. doi: 10.3389/fimmu.2021.672356. PMID: 33936118; PMCID: PMC8085349.
  60. Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol. 2022 Jan 28;13:828386. doi: 10.3389/fimmu.2022.828386. PMID: 35154149; PMCID: PMC8831788.
  61. Disis ML, Cecil DL. Breast cancer vaccines for treatment and prevention. Breast Cancer Res Treat. 2022 Feb;191(3):481-489. doi: 10.1007/s10549-021-06459-2. Epub 2021 Nov 30. PMID: 34846625.
  62. McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2021 Jul;21(7):903-913. doi: 10.1080/14712598.2021.1840547. Epub 2020 Dec 27. PMID: 33089726.
  63. Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023 Mar;43(3):297-337. doi: 10.1002/cac2.12387. Epub 2022 Nov 10. PMID: 36357174; PMCID: PMC10009672.
  64. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. PMID: 33081383; PMCID: PMC7587605.
  65. Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2023 Feb 17;15(4):1278. doi: 10.3390/cancers15041278. PMID: 36831621; PMCID: PMC9954407.
  66. Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18. PMID: 36302269; PMCID: PMC9614644.
  67. Naidoo K, Parham DM, Pinder SE. An audit of residual cancer burden reproducibility in a UK context. Histopathology. 2017 Jan;70(2):217-222. doi: 10.1111/his.13054. Epub 2016 Sep 27. PMID: 27496095.
  68. Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. PMID: 34902335; PMCID: PMC9455620.
  69. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Erratum in: Lancet. 2019 Mar 9;393(10175):986. PMID: 24529560.
  70. Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surg. 2018 Dec 1;153(12):1120-1126. doi: 10.1001/jamasurg.2018.2696. PMID: 30193375; PMCID: PMC6583006.
  71. Bai YG, Gao GX, Zhang H, Zhang S, Liu YH, Duan XN, Xu L. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. Chin Med J (Engl). 2020 Mar 5;133(5):552-560. doi: 10.1097/CM9.0000000000000656. PMID: 32044815; PMCID: PMC7065871.
  72. Stecklein SR, Kimler BF, Yoder R, Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab J, Home T, Hyter S, Isakova K, Pathak HB, Godwin AK, Sharma P. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ Breast Cancer. 2023 Mar 6;9(1):10. doi: 10.1038/s41523-023-00512-7. PMID: 36878909; PMCID: PMC9988835.
  73. Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS One. 2020 Jun 24;15(6):e0234191. doi: 10.1371/journal.pone.0234191. PMID: 32579551; PMCID: PMC7313974
  74. Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Curr Treat Options Oncol. 2021 Jul 2;22(9):79. doi: 10.1007/s11864-021-00879-4. PMID: 34213636.

Photo
Prudence A Rodrigues
Corresponding author

Professor, department of pharmacy practice, PSGcollege of pharmacy

Photo
Preethi nivedhaa A
Co-author

Psg college of pharmacy

Photo
Sneha B
Co-author

Psg college of pharmacy

Photo
Ranjith kumar P
Co-author

Psg college of pharmacy

Prudence A. Rodrigues, Preethi A. Nivedhaa, Sneha B., Ranjith P. Kumar, Solubility Enhancement, Prognostic Biomarkers For Triple Negative Breast Cancer: A Narrative Review,Int. J. of Pharm. Sci., 2024, Vol 2, Issue 1, 311-327. https://doi.org/10.5281/zenodo.10523663

More related articles
Data Integrity Compliance, Importance, Consequence...
Sanket Gade, Dr. Prerana Jadhav, Dr. Pradyumana Ige, Pratiksha Bo...
Effects Of Ethanol Extract From Foeniculum Vulgare...
Jadhav Supriya , Padmaja giram , Patil nitin , Poulkar madhuri , ...
Formulation And Evaluation Of Insitu Forming Float...
Abarajitha. T, K. L. Senthil Kumar, ...
View more
A Brief Review On Emulgel...
Abishek jhariya , Najneen Dubey, Shubhangi Nema, Bharti Choudhary, ...
A Comprehensive View Of Kaffir Lime (Citrus Hystrix)...
K.MOUNIKA, K.B ILANGO, M.J DHARANI PRABHA, S.EDVIN SHERIN, K.P PRAVEEN, T.TAMILARASI, ...
Oncopathology And Cancer Immunotherapy...
Mayuri N Jagtap, Vishesh Nitin Raundal, Avinash B. Darekar, ...
View more
Download PDF
Related Articles
Formulation and Evaluation of Floating Microspheres Containing Non-Steroidal Ant...
Muggu Sankara bhavani, K. ChandraSekhar Gupta, A. Brahma Reddy, G. Venkata Vasu, ...
A new approach in the drug carrier system: Aquasomes...
Belna Augustine, Mrs Aswathy C, Shilpa KD, Mrs Naseena U, ...
Investigating an Out of Specifications results – The most challenging function...
Abhinav Sawant, Amey Bhosale, Tejashri Kamble, Dr. Nilesh Chougule, ...
The Evaluation of Antibiotic Resistance: Mechanisms, Challenges, and Future Dire...
Sanika shivling chougule , ...
Data Integrity Compliance, Importance, Consequences And Strategy To Overcome Dat...
Sanket Gade, Dr. Prerana Jadhav, Dr. Pradyumana Ige, Pratiksha Bornare, ...
More related articles
Data Integrity Compliance, Importance, Consequences And Strategy To Overcome Dat...
Sanket Gade, Dr. Prerana Jadhav, Dr. Pradyumana Ige, Pratiksha Bornare, ...
Effects Of Ethanol Extract From Foeniculum Vulgare On Human Mecenchymal Stem Cel...
Jadhav Supriya , Padmaja giram , Patil nitin , Poulkar madhuri , Pawar chaitanya , ...
Formulation And Evaluation Of Insitu Forming Floating Gel Of Olanzapine For The ...
Abarajitha. T, K. L. Senthil Kumar, ...
View more
Data Integrity Compliance, Importance, Consequences And Strategy To Overcome Dat...
Sanket Gade, Dr. Prerana Jadhav, Dr. Pradyumana Ige, Pratiksha Bornare, ...
Effects Of Ethanol Extract From Foeniculum Vulgare On Human Mecenchymal Stem Cel...
Jadhav Supriya , Padmaja giram , Patil nitin , Poulkar madhuri , Pawar chaitanya , ...
Formulation And Evaluation Of Insitu Forming Floating Gel Of Olanzapine For The ...
Abarajitha. T, K. L. Senthil Kumar, ...
View more

Copyright © 2024 IJPS. All rights reserved